Synthesis and evaluation of tricyclic dipyrido diazepinone derivatives as inhibitors of secretory phospholipase A2 with anti-inflammatory activity

Current Topics in Medicinal Chemistry

Volumn 7, Issue 8, 2007, Pages 811-820

  Thimmegowda, N R ^a   Dharmappa, K K ^a   Anandra Kumar, C S ^a   Sadashiva, M P ^a   Sathish, A D ^a   Nanda, B L ^a   Vishwanath, B S ^a   Rangappa, K S ^a  

^a UNIVERSITY OF MYSORE   (India)

Author keywords

Antiinflammatory; Phospholipase A2 inhibition; Tricyclic dipyrido diazepinone

Indexed keywords

10 (2 BROMO 4,5 DIMETHOXYBENZYL) 7 CHLORO 5 CYCLOPROPYL 9 METHYL 5,10 DIHYDRO 4,5,6,10 TETRAAZADIBENZOCYCLOHEPTEN 11 ONE; 4 (7 CHLORO 5 CYCLOPROPYL 9 METHYL 11 OXO 5,10 DIHYDRO 4,5,6,10 TETRAAZADIBENZOCYCLOHEPTEN 10 YLMETHYL)BENZONITRILE; 7 CHLORO 5 CYCLOPROPYL 10 (4 METHOXY 3,5 DIMETHYLPYRIDINE 2 YLMETHYL) 9 METHYL 5,10 DIHYDRO 4,5,6,10 TETRAAZADIBENZOCYCLOHEPTEN 11 ONE; 7 CHLORO 5 CYCLOPROPYL 9 METHYL 10 (2 NITRO 4 TRIFLUROMETHYLPHENYL) 5,10 DIHYDRO 4,5,6,10 TETRAAZADIBENZOCYCLOHEPTEN 11 ONE; 7 CHLORO 5 CYCLOPROPYL 9 METHYL 10 (2 OXO 2 PYRIDIN 3 YLETHYL) 5,10 DIHYDRO 4,5,6,10 TETRAAZADIBENZOCYCLOHEPTEN 11 ONE; 7 CHLORO 5 CYCLOPROPYL 9 METHYL 10 (2 PYRROLIDINE 1 YLETHYL) 5,10 DIHYDRO 4,5,6,10 TETRAAZADIBENZOCYCLOHEPTENE 11 ONE; 7 CHLORO 5 CYCLOPROPYL 9 METHYL 5,10 DIHYDRO 4,5,6,10 TETRAAZADIBENZOCYCLOHEPTEN 11 ONE; ANTIINFLAMMATORY AGENT; CALCIUM; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; SNAKE VENOM; TRICYCLIC DIPYRIDODIAZEPINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME SUBSTRATE; HEMOLYSIS; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; PAW EDEMA; PLEURA FLUID; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AZEPINES; EDEMA; ENZYME INHIBITORS; HEMOLYSIS; INHIBITORY CONCENTRATION 50; MICE; PHOSPHOLIPASES A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247560277     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780487650     Document Type: Review

References (47)

1. Dennis, E. A. Phospholipases. In P. Boyer, editor. The Enzymes, Academic Press, New York, 3rd ed., 1983, Vol. 16, 307-353.
2. 2 and signal transduction. J. Am. Soc. Nephrol. 1992, 3, 128-150.
3. 2 (S); comparison of arachidonoyl selective and non selective enzyme. FASEB J. 1993, 7, 339-348.
4. Dennis, E. A. Diversity of group types, regulation and function of phospholipase A2. J. Biol. Chem. 1994, 269, 13057-13060.
5. Six, D.A.; Dennis, E.A. The expanding super family of phospholipase A(2) enzymes: Classification and characterization. Biochim. Biophys. Acta 2000, 1488, 1-19.
6. 2 super family of signal transduction enzymes. Trends Biochem. Sci. 1997, 22 1-2.
7. 2 in inflammation. Adv. Inflam. Res. 1984, 7, 51-59.
8. 2; from snake-venom to human secreted forms. J. Mol. Evol. 1990, 31, 228-238.
9. 2 and arthritis. Arthritis Rheum. 1993, 36, 190-198,
10. 2 that participate in the destruction of Escherichia coli in a rabbit inflammatory exudates. J. Biol. Chem. 1990, 265, 6675-6681.
11. 2 purified from human synovial fluid and inhibition by aristolochic acid. Inflammation 1988, 12, 549-561.
12. 2 induces an inflammatory response in rabbit joints. J. Immunol. 1991, 146, 3904-3939.
13. 2 enzymes from haba (Trimeresurus flavovoridis) venom and their interaction with the alkaloid aristolochic acid. Toxicon 1987, 25, 501-515,
14. 2 with anti-inflammatory activity. Int. J. Mol. Med. 2005, 16 895-904.
15. 2 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3679-3682.
16. Yongqin, W.; Wooyoung, H.; Charles, Y. C.; Yi, L.; Francisco, J. A.; Livier, L. S. B.; Thomas, M. D. F.; Laurent, M.; Nathanael, S. G. Synthesis and Target Identification of Hymenialdisine. Anal. Chem. Biol. 2004, 11, 247-259.
17. Stochla, K.; Dorociak, A.; Makulska, H. E. Analgesic and antiinflammatory properties of the pirolo-[3,4-e][1,4]-diazepine derivatives. Pol. J. Pharmacol. Pharm. 1984, 36, 665-74.
18. Yoakim, C. P.; Bonneau, R.; Deziel, R.; Doyon, L.; Duan, J.; Guse, I.; Landry, S.; Malenfant, E.; Naud, J.; Ogilvie, W. W.; O'Meara, J. A.; Plante, R.; Simoneau, B.; Thavonekham, B.; Bos, M.; Cordingley, M. G. Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthio-methyldipyridodiazepinone derivatives. Bio-org. Med. Chem. 2004, 14, 739-742.
19. Karl, D. H.; John, R. P.; Karl, G. G.; Ernest, C.; Suresh, R. K.; Usha, R. P.; Victor, U. F.; Scott, C. M.; Jana, V.; Mark, L. B.; Janice, M. K.; Kollol, P.; Jerry, W. S.; Daniel, W. M.; Janice, M. R.; Grace, C. C.; Mark, T. S.; Joe, C. W.; Giinther, S.; Wolfhard, W. E.; Wolfgang, G. E.; Tracy, D. S.; Scot, J. C.; Alan, S. R.; Julian, A. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones. J. Med. Chem. 1991 34, 2231-2241.
20. Charles, L. C.; Janice, M. K.; MaryAnn, H.; Janice, R. B.; Eva, D.; Peter, M. G.; Racheline, S.; Daniel, P.; Kevin, J. B.; Cheng-Kon, S.; Christopher, L. S.; David, A. E.; David, P. J.; Susan, E. H. Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 8.8-Aryloxymethyl- and 8- Arylthiomethyl dipyridodiazepinones1 J. Med. Chem. 1998, 41, 2972-2984.
21. Baraldi, P.G.; Leoni, A.; Cacciari, B.; Manfredini, S.; Simoni D.; Bergami, D.; Menta, M.; Spinelli, S. Synthesis and Antitumor activity of a new class of Pyrazolo[4,3-e]pyrrolo[1,2-a][1,4] diazepinone analogs of Pyrrolo[1,4] benzodiazepines (PBDs). J. Med. Chem. 1994, 37, 4329-4337.
22. Razminia, M.; Salem, Y.; Devaki, S.; Shah, N.; Khosla, S. Clozapine Induced Myopericarditis: Early Recognition Improves Clinical Outcome. Am. J. Therapeut. 2006, 13(3), 274-276.
23. Matsumoto, J.; Miyamoto, T.; Minamida, A.; Nishimura, Y.; Egawa, H.; Nishimura, H. Synthesis of Fluorinated Pyridines by the Balz-Schiemann Reaction. An Alternative Route To Enoxacin, A New Antibacterial Pyridone carboxylic Acid. J. Heterocycl. Chem. 1984, 21, 673-679.
24. 2 from Russell's viper (Vipera ruselli) venom. Toxicon 1989, 27, 229-237.
25. 2 from IndianCobra (Naja naja naja) venom. Toxicon 1992, 30, 1227-1238.
26. Ragupathi, R.; Franson, R.C. Isolation of a Ca2+-dependentphospholipase A2 from human platelets. Fed. Proc. 1987, 46, 1945-1951.
27. 2 enzyme. Nephrol. Dial. Transplant. 1996, 11, 109-116.
28. Boman, H.G.; Kaletta, U. Chromatography of rattlesnakevenom, a separation of three phosphodiesterases. Biochim. Biophys. Acta. 1957, 24, 619-631
29. Yamakawa, M.; Nozaki, M.; Hokoma, Z. Fractionation of sakishima-habu (Trimeresurus elegans) venom and lethalhemorrhagic and edema forming activity of the fractions. In: Animal Plant and Microbial Toxins. Ohsaka A, Hayashi K and Sawai Y (eds). Plenum Press, New York, 1976, Vol I., 97-109.
30. 2. Biochemistry 1993, 32, 6485-6492.
31. 2 enzyme by bilirubin: A new role as endogenous anti-inflammatory molecule. Mol. Cell. Biochem. 2005, 1-7.
32. 2 with anti-inflammatory activity. Life Sci. 2006, 80(2), 146-53.
33. 2 in human synovial fluid and arachidonic acid release from rat peritoneal macrophages. Inflammation 1985, 14, 543-559.
34. Chandra, V.; Jasti, J.; Kaur, P.; Betzel, CH.; Srinivasan, A.; Singh, T. P. First structural evidence of a specific inhibition of phospholipase A2 by alpha- tocopherol (vitamin E) and its implications in inflammation: Crystal structure of the complex formed between phospholipase A2 and alpha-tocopherol at 1.8 A resolution. J. Mol. Bio. 2002, 320(2) 215-221.
35. 2 activity. A monolayer study. Biochim. Biophys. Acta 1985, 1026, 179-185.
36. 2. Mol. Pharmacol. 2004, 65, 964-972.
37. 2 activity by unsaturated fatty acids. Proc Natl. Acad. Sci. 1985, 8, 371-375.
38. De Rosa, M.; Giordano, S.; Scettri, A.; Sodano, G.; Soriente, A.; Garcia Pastor, P.; Alcaraz, M. J.; Paya, M. Synthesis and Comparison of the anti- inflammatory activity of Manoalide and Cacospongionolide B analogues. J. Med. Chem. 1998, 41, 3232-3238.
39. 2 and inflammation responses in mice. Life Sci. 1994, 54, 333-338.
40. 2. Biochem. Pharmacol. 1988, 55, 975-985.
41. 2 from Vipera russelli venom with aristolochic acid. A circular dichroism study. Toxicon 1987, 25, 939-946.
42. 2 inhibitor, on acute and chronic inflammation. JPET. 1999, 289, 166-172.
43. 2 enzymes. Biochem. J. 1996, 320, 93-99.
44. Nicolaou, A.; Kokotos, G.; Constantinou-Kokotou, V.; Charitos, C.; Noula, C.; Verger, R.; Gibbons, W. A. Synthesis and properties of novel lipopeptides and lipid mimetics.J. Pept. Sci. 1997, 3 291-298.
45. 2 enzymes from habu (Trimeresurus flavovoridis) venom and their interaction with the alkaloid aristolochic acid. Toxicon 1987, 25, 501-515.
46. 2 purified from human synovial fluid and inhibition by aristolochic acid. Inflammation 1988, 12, 549-561.
47. 2 inhibitors. Fed. Proc. 1987, 46, 854-862.